Albireo Pharma is a biopharmaceutical company that specializes in developing innovative bile acid modulators for the treatment of rare pediatric liver diseases, as well as other liver and gastrointestinal disorders. The company's lead product candidate, odevixibat, is currently in Phase 3 development for treating rare cholestatic liver diseases in children, including progressive familial intrahepatic cholestasis and biliary atresia. Albireo Pharma was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with a subsidiary in Gothenburg, Sweden. The company has been recognized as one of the best places to work in Massachusetts by the Boston Business Journal for two years running.